Oculis Holding AG (OCS) stock

OCSNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as OCSAW

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 4, 2026Score 1/30

$7.64+0.14 (+1.87%)

Close on Nov 13, 2026Market cap $459.08MP/E –Yield –

Oculis ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Oculis has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?